Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: A randomized, double-blind, active-controlled, parallel-group, US-based multicenter study

Contraception

Volumn 85, Issue 1, 2012, Pages 42-50

  Bart Sr , Stephan ^a   Marr, Joachim ^b   Diefenbach, Konstanze ^b   Trummer, Dietmar ^b   Sampson Landers, Carole ^c  

^a SNBL Clinical Pharmacology Center   (United States)

^b BAYER PHARMA AG   (Germany)

^c Bayer Healthcare Pharmaceuticals Inc   (United States)

Author keywords

Drospirenone; Ethinylestradiol; Folates; Neural tube defects; Oral contraceptives

Indexed keywords

CALCIUM SALT; DROSPIRENONE PLUS ETHINYLESTRADIOL; FOLIC ACID; HOMOCYSTEINE; LEVOMEFOLATE CALCIUM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRONCHITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHROCYTE; FEMALE; FOLIC ACID BLOOD LEVEL; GENITAL BLEEDING; HUMAN; INFLUENZA; LIBIDO; MIGRAINE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; ORAL CONTRACEPTION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DYSPLASIA; WART VIRUS;

ADOLESCENT; ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; CALCIUM; CONTRACEPTIVES, ORAL; DOUBLE-BLIND METHOD; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; FOLIC ACID; GLUTAMATES; HOMOCYSTEINE; HUMANS; NEURAL TUBE DEFECTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82755161008     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2011.05.013     Document Type: Article

References (42)

1. H. Northrup, and K.A. Volcik Spina bifida and other neural tube defects Curr Probl Pediatr 30 2000 313 332
2. R. Padmanabhan Etiology, pathogenesis and prevention of neural tube defects Congenit Anom (Kyoto) 46 2006 55 67
3. L.D. Botto, C.A. Moore, M.J. Khoury, and J.D. Erickson Neural-tube defects N Engl J Med 341 1999 1509 1519 (Pubitemid 29526355)
4. N.J. Wald, M.R. Law, J.K. Morris, and D.S. Wald Quantifying the effect of folic acid Lancet 358 2001 2069 2073 (Pubitemid 34084836)
5. M. Eichholzer, O. Tonz, and R. Zimmermann Folic acid: a public-health challenge Lancet 367 2006 1352 1361
6. L.E. Daly, P.N. Kirke, A. Molloy, D.G. Weir, and J.M. Scott Folate levels and neural tube defects. Implications for prevention JAMA 274 1995 1698 1702
7. MRC Vitamin Study Research Group Prevention of neural tube defects: results of the Medical Research Council Vitamin Study Lancet 338 1991 131 137
8. A.E. Czeizel, and I. Dudas Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation N Engl J Med 327 1992 1832 1835 (Pubitemid 23003073)
9. R.W. Smithells, S. Sheppard, and C.J. Schorah Possible prevention of neural-tube defects by periconceptional vitamin supplementation Lancet 1 1980 339 340 (Pubitemid 10219521)
10. R.J. Berry, Z. Li, and J.D. Erickson Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention N Engl J Med 341 1999 1485 1490
11. Centers for Disease Control and Prevention (CDC) Racial/ethnic differences in the birth prevalence of spina bifida - United States, 1995-2005 MMWR Morb Mortal Wkly Rep 57 2009 1409 1413
12. T.J. Mathews, M.A. Honein, and J.D. Erickson Spina bifida and anencephaly prevalence - United States, 1991-2001 MMWR Recomm Rep 51 2002 9 11
13. T. Mathews Trends in spina bifida and anencephalus in the United States, 1991-2006 [cited 12 April 2011]; Available from: http://www.cdc.gov/nchs/data/ hestat/spine-anen/spine-anen.pdf 2009
14. U.S. Preventive Services Task Force Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 150 2009 626 631
15. Centers for Disease Control and Prevention (CDC) Use of supplements containing folic acid among women of childbearing age - United States, 2007 MMWR Morb Mortal Wkly Rep 57 2008 5 8
16. L. Evans, and C.S. Weisman Folic acid supplementation in younger and older nonpregnant women of reproductive age: findings from the Central Pennsylvania Women's Health Study (CePAWHS) Womens Health Issues 20 2010 50 57
17. S.C. Tinker, M.E. Cogswell, O. Devine, and R.J. Berry Folic acid intake among U.S. women aged 15-44 years, National Health and Nutrition Examination Survey, 2003-2006 Am J Prev Med 38 2010 534 542
18. Food & Drug Administration Summary minutes: Advisory Committee for Reproductive Health Drugs meeting, December 15, 2003 [cited 12 April 2011]; Available from: http://www.fda.gov/ohrms/dockets/ac/03/minutes/4002M1-Final.pdf
19. P. Barjot, O. Graesslin, D. Cohen, P. Vaillant, P. Clerson, and M. Hoffet Pregnancies occurring during oral contraception: lessons from the GRECO study [Article in French] Gynecol Obstet Fertil 34 2006 120 126 (Pubitemid 43339585)
20. M. Cronin, I. Schellschmidt, and J. Dinger Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives Obstet Gynecol 114 2009 616 622
21. S. Verbiest Folic acid fortification: should oral contraceptives be next? MCN Am J Matern Child Nurs 30 2005 228
22. M.J. Rosenberg, M.S. Waugh, and M.S. Burnhill Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation Fam Plann Perspect 30 1998 89 92 104
23. Data on file, Bayer HealthCare Pharmaceuticals. Clinical study report number A27410 (protocol number 309662). 30 Jun 2008.
24. Data on file, Bayer HealthCare Pharmaceuticals. Clinical study report number A28575 (protocol number 309664). 10 Nov 2008.
25. K. Diefenbach, D. Trummer, F. Ebert, M. Lissy, B. Rohde, and H. Blode Changes in folate levels following cessation of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg co-administration Eur J Contracept Reprod Health Care 15 2010 157 158
26. K. Diefenbach, D. Trummer, F. Ebert, M. Lissy, B. Rohde, and H. Blode Changes in folate levels following a 24-week co-administration of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg Eur J Contracept Reprod Health Care 15 2010 158 159
27. S.E. Vollset, H. Refsum, and L.M. Irgens Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study Am J Clin Nutr 71 2000 962 968 (Pubitemid 30176580)
28. P.M. Castaño, and C.L. Westhoff A new tool for assessing the folate status of reproductive-aged urban Latina women Obstet Gynecol 107 2006 44S 45S [Presented at the American College of Obstetricians and Gynecologists [ACOG] 55th Annual Clinical Meeting, May 8, 2006; San Diego, CA, USA]
29. Centers for Disease Control and Prevention (CDC) Spina bifida and anencephaly before and after folic acid mandate - United States, 1995-1996 and 1999-2000 MMWR Morb Mortal Wkly Rep 53 2004 362 365
30. Y. Lamers, R. Prinz-Langenohl, R. Moser, and K. Pietrzik Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women Am J Clin Nutr 79 2004 473 478 (Pubitemid 41115593)
31. B.J. Venn, T.J. Green, R. Moser, J.E. McKenzie, C.M. Skeaff, and J. Mann Increases in blood folate indices are similar in women of childbearing age supplemented with [6S]-5-methyltetrahydrofolate and folic acid J Nutr 132 2002 3353 3355 (Pubitemid 35304243)
32. K. Pietrzik, Y. Lamers, S. Bramswig, and R. Prinz-Langenohl Calculation of red blood cell folate steady state conditions and elimination kinetics after daily supplementation with various folate forms and doses in women of childbearing age Am J Clin Nutr 86 2007 1414 1419 (Pubitemid 350126246)
33. Data on file, Bayer HealthCare Pharmaceuticals. Clinical study report number A43598 (protocol number 310662). 2 Jul 2009.
34. U.S. Preventive Services Task Force Screening for neural tube defects - including folic acid/folate prophylaxis US Preventive Services Task Force Guide to Clinical Preventive Services 2nd ed. 1996 Williams & Wilkins Baltimore 467 483
35. Y. Lamers, R. Prinz-Langenohl, S. Bramswig, and K. Pietrzik Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age Am J Clin Nutr 84 2006 156 161 (Pubitemid 44699180)
36. B.J. Venn, T.J. Green, R. Moser, and J.I. Mann Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled study Am J Clin Nutr 77 2003 658 662 (Pubitemid 36258576)
37. K. Pentieva, H. McNulty, and R. Reichert The short-term bioavailabilities of [6S]-5-methyltetrahydrofolate and folic acid are equivalent in men J Nutr 134 2004 580 585 (Pubitemid 38298499)
38. R. Prinz-Langenohl, A. Bronstrup, B. Thorand, M. Hages, and K. Pietrzik Availability of food folate in humans J Nutr 129 1999 913 916 (Pubitemid 29162389)
39. L. Anttila, M. Kunz, and J. Marr Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive Contraception 80 2009 445 451
40. G. Bachmann, P.J. Sulak, C. Sampson-Landers, N. Benda, and J. Marr Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone Contraception 70 2004 191 198 (Pubitemid 39119980)
41. L. Hernadi, J. Marr, D. Trummer, V. De Leo, and F. Petraglia Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen Contraception 80 2009 18 24
42. J.M. Maloney, P. Dietze Jr., and D. Watson Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial Obstet Gynecol 112 2008 773 781